Skip to content

Ocular Surface Changes in Patients With Cystic Fibrosis

Chosen Parameters of the Immune Response in the Origin of Ocular Changes in Patients With Cystic Fibrosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00345280
Enrollment
26
Registered
2006-06-28
Start date
2006-08-31
Completion date
2008-09-30
Last updated
2008-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Manifestations

Keywords

Cystic fibrosis, eye, inflammation, apoptosis, C11+

Brief summary

Cystic fibrosis(CF) is an inherited disease affecting children, adolescents and young adults with dysfunction of secretory glands.It is caused by mutations in the protein-coding gene which function as the cystic fibrosis transmembrane regulator (CFTR), responsible for the secretion of chloride ions in epithelial cells, adenocytes, sweat gland cells, pancreatic ducts,alimentary and respiratory tracts and eye. Assessment of the relationship between the inflammatory processes and apoptosis in the eye in the course of cystic fibrosis will allow determination of immunological exponents which may facilitate diagnosis.

Detailed description

The aim: To assess the role of chosen parameters of immunological response in the induction of ocular changes in cystic fibrosis patients, particularly chosen chemokine concentrations in the tear fluid and analysis of chosen apoptotic markers expression on conjunctival epithelial cells.

Interventions

PROCEDUREimpression cytology, obtain the tear fluid

Vitamin A

Sponsors

University of Bialystok
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* male and female patients aged 3-25 with clinically definite diagnosis of cystic fibrosis * all patients must give written consent for participation in the study at screening

Exclusion criteria

* patients with a history of chronic disease of the immune system * patients with the history of systemic diseases * patients with the history chronic ocular diseases * patients who have been treated with corticosteroids in the past 3 months prior to the screening visit

Countries

Poland

Contacts

Primary ContactMichal Sewerynski, Prof.
minister@mnisw.gov.pl+48 22 6281944

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026